Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2002
07/04/2002US20020086345 Methods and compositions for the visualization of cellular organelles using tetrazolium salts
07/04/2002US20020086332 Method of reducing bacterial proliferation
07/04/2002US20020086315 Method of determining a chemotherapeutic regimen based on ERCC1 expression
07/04/2002US20020086308 Ribosome crystaline structure; for use in killing or prevention of propagation of target organism
07/04/2002US20020086067 Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
07/04/2002US20020086065 Methods and compositions for the benefit of those suffering from polycystic ovary syndrome with chromium complexes
07/04/2002US20020086061 Forming a drug containing core by compressing comprising granulated microparticles of felodipine and cyclodextrin, carrier comprising cyclodextrin particles, a water-insoluble alkaline component and a swellable polymer
07/04/2002US20020086059 Dissolving solid material in dimethyl ether under a pressure and heating; reducing pressure on solution to precipitate the solid material as pulverous formulation and to expand dimethyl ether into a gas, separating
07/04/2002US20020086057 For therapy of urinary incontinence
07/04/2002US20020086056 Tablet containing a coated core
07/04/2002US20020086053 As antidepressant
07/04/2002US20020086052 Rapidly disintegrating methylcellulose tablets
07/04/2002US20020086049 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
07/04/2002US20020086048 Design and application method for enhanced oral assimilation through the oral mucosa and/or intestinal membranes, of liquids containing nutrients, nutraceuticals or drugs, which are encapsulated in natural and/or synthetic liposomal vesicles
07/04/2002US20020086041 Hydroxydecenoic acid compounds for promoting desquamation/epidermal renewal of the skin and/or combating skin aging
07/04/2002US20020086038 Long-lasting styling mousse
07/04/2002US20020086032 Administering immunogenic dose of attenuated bacteria comprising altered DNA adenine methylase (Dam) activity relative to a wild-type bacteria for generating immune response and produce antibodies
07/04/2002US20020086029 For use in inhibiting gastric acid secretion; therapy of gastric acid related diseases
07/04/2002US20020086020 Method for improving the half-life of soluble viral receptors on mucosal membranes
07/04/2002US20020086016 Diagnostic methods based upon a particular genotype in the Tumor Necrosis Factor (TNF alpha ) gene
07/04/2002US20020086015 Compositions and methods for promoting nerve regeneration
07/04/2002US20020086013 Administering an agent that inhibits a component of the VEGF signal transduction pathway; agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
07/04/2002US20020086011 Administering an effective amount of an OX-2 protein or a nucleic acid encoding an OX-2 protein; use to suppress an immune response and to prevent or treat autoimmune disease, especially arthritis.
07/04/2002US20020085997 Tumor cells at least some of which contain at least one MHC-I-haplotype of the patient on the cell surface, and which are charged with one or more peptides binding to the MHC-I molecule
07/04/2002US20020085995 In vivo induction for enhanced function of isolated hepatocytes
07/04/2002US20020085978 Containing a propellant, a cosolvent, and a radical quencher.
07/04/2002US20020085615 Differential scanning calorimeter
07/04/2002US20020084221 Method for precipitating red blood cells
07/04/2002DE10150312A1 New 2-(m-amino-phenylimino)-imidazolidine derivatives, are potent and selective alpha-1L agonists useful for treating bladder disorders, especially urinary incontinence
07/04/2002DE10130128A1 Treatment of herpes zoster infections or post-herpetic neuralgia by once-daily oral administration of brivudine, giving superior results to higher dose and more frequent administration of acyclovir
07/04/2002DE10065710A1 Arzneimittel enthaltend ein Polyamin als Wirksubstanz A medicament comprising a polyamine as the active substance
07/04/2002DE10065482A1 New heavier halogen atom substituted squarane dyes, used as photosensitizer in photodynamic therapeutical applications, fluorescent detector of tumors and sensitizer in water sterilization
07/04/2002DE10064994A1 Sulfamidothienopyrimidine Sulfamidothienopyrimidine
07/04/2002DE10064993A1 Drug formulation useful e.g. for treating angina or hypertension contains pyrazolo (4,3-d) pyrimidine derivative phosphodiesterase V inhibitor and antithrombotic agent, calcium antagonist or prostaglandin
07/04/2002DE10064453A1 Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases
07/04/2002DE10063435A1 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Chinazolinderviate, medicaments containing these compounds, their use and process for their preparation
07/04/2002DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases
07/04/2002DE10059144A1 Modulation der Transkription pro-inflammatorischer Genprodukte Modulating the transcription of pro-inflammatory gene products
07/04/2002DE10044649A1 Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine Substituted 4-phenyl-1- (1-phenylcyclohexyl) -1,2,3,6-tetrahydropyridines
07/04/2002CA2782510A1 Polypeptides
07/04/2002CA2626317A1 Crystalline forms of atorvastatin
07/04/2002CA2623600A1 Crystalline forms of atorvastatin
07/04/2002CA2623599A1 Crystalline forms of atorvastatin
07/04/2002CA2622727A1 Crystalline forms of atorvastatin
07/04/2002CA2622697A1 Crystalline forms of atorvastatin
07/04/2002CA2622477A1 Crystalline forms of atorvastatin
07/04/2002CA2441896A1 Quinuclidine carbamate derivatives and their use as m3 antagonists
07/04/2002CA2437209A1 Remedies for hepatitis c
07/04/2002CA2436739A1 Combination agent
07/04/2002CA2433861A1 Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
07/04/2002CA2433520A1 Novel compounds and compositions as cathepsin inhibitors
07/04/2002CA2433264A1 Agent for treating and/or preventing diseases due to retinal ischemia
07/04/2002CA2433259A1 Azole compounds as anti-fungals agents
07/04/2002CA2433220A1 Novel purine derivatives, preparation method and use as medicines
07/04/2002CA2433138A1 Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
07/04/2002CA2433100A1 Indole derivatives as ligands of thyroid receptors
07/04/2002CA2432896A1 Thermoformable solid pharmaceutical composition for controlled release of perindopril
07/04/2002CA2432661A1 Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
07/04/2002CA2432654A1 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
07/04/2002CA2432645A1 Thermoformable solid pharmaceutical composition for controlled release of ivabradine
07/04/2002CA2432644A1 Pharmaceutical composition comprising aspirintm and cs-747
07/04/2002CA2432570A1 New clinical treatment
07/04/2002CA2432543A1 Combination drugs
07/04/2002CA2432536A1 Angiogenesis inhibitor
07/04/2002CA2432527A1 Medicinal compositions for oral use
07/04/2002CA2432523A1 Compositions of stable t3 and methods of use thereof
07/04/2002CA2432518A1 Treatment of inoperable tumors by stereotactic injection of microspheres
07/04/2002CA2432473A1 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders
07/04/2002CA2432008A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands
07/04/2002CA2431953A1 Piperidine mch antagonists and their use in the treatment of obesity
07/04/2002CA2431906A1 Process to improve stability of a pharmaceutical composition
07/04/2002CA2431883A1 Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof
07/04/2002CA2431835A1 Induction of tolerance
07/04/2002CA2431471A1 Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
07/04/2002CA2431415A1 Divalproex sodium dosage forms and a process for their production
07/04/2002CA2431375A1 Solid dosage forms of divalproex sodium
07/04/2002CA2430930A1 Helicobacter proteins, nucleic acids and uses thereof
07/04/2002CA2430691A1 Immunomodulatory polynucleotides and methods of using the same
07/04/2002CA2429773A1 Aerogel powder comprising therapeutic agents
07/04/2002CA2429709A1 Motilide compounds
07/03/2002EP1219709A1 Nucleozymes
07/03/2002EP1219708A1 Modulate aptamer and method for detecting target protein by using the same
07/03/2002EP1219638A2 G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1)
07/03/2002EP1219632A1 Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds
07/03/2002EP1219630A1 Immunopotentiating compositions
07/03/2002EP1219624A1 Remedies for neuropathic pain and model animals of neuropathic pain
07/03/2002EP1219623A1 New esters derived from substituted phenyl-cyclohexyl compounds
07/03/2002EP1219622A2 Pharmaceutical compositions for CNS and other disorders
07/03/2002EP1219614A1 Benzene sulfonamides as PDE-V inhibitors for the use against erectile dysfunction
07/03/2002EP1219612A1 2-imino-1,3-thiazine derivatives
07/03/2002EP1219609A1 Aromatic nitrogenous six-membered ring compounds
07/03/2002EP1219606A1 Tricyclic compounds bearing acyloxymethoxycarbonyl pendants
07/03/2002EP1219604A1 Method for improving the solubility of tricyclic amino alcohol derivatives
07/03/2002EP1219594A1 New esters derived from substituted phenyl-cyclohexyl compounds
07/03/2002EP1219306A1 Compositions comprising cyclodextrins and NO- releasing drugs
07/03/2002EP1219304A2 Stable parenteral solution containing diclofenac salts, their preparation and use therof
07/03/2002EP1219302A1 Trapping agent for blood carbonyl compounds
07/03/2002EP1219297A1 Antiobestic agents
07/03/2002EP1219296A1 Sebum production inhibitors
07/03/2002EP1219295A1 Controlled release formulation of valproate